<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04359732</url>
  </required_header>
  <id_info>
    <org_study_id>Escape</org_study_id>
    <nct_id>NCT04359732</nct_id>
  </id_info>
  <brief_title>Prediction of Assessment of Response to nCRT for Esophageal and Gastroesophageal Junction Cancer Using a Fully Integrated PET/MRI</brief_title>
  <acronym>Escape</acronym>
  <official_title>Prediction of Assessment of Response to Neoadjuvant Chemo-Radio-Therapy (nCRT) for Esophageal and Gastroesophageal Junction Cancer (GEJ) Using a Fully Integrated PET/MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIRC -FONDAZIONE AIRC PER LA RICERCA SUL CANCRO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the potential role of PET/MRI as a predictor of esophageal and junctional cancers in
      response to neoadjuvant chemoradiotherapy (nCRT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, observational single center study which plans to enroll patients with
      biopsy proven potentially resectable esophageal or junctional cancer scheduled to receive
      nCRT (CROSS regimen) prior to surgery.

      The study aims to evaluate Routine pre-treatment work-up includes PET to stage the tumour
      extension.

        -  PET/MRI (Magnetic resonance imaging) will replace the PET component of CT(computed
           tomography)

        -  An additional intermediate 18-FDG (Fluorodeoxyglucose) PET/MRI will be performed during
           nCRT

        -  Post nCRT imaging, as required prior to surgery, will be PET/MRI six weeks after
           treatment completion.

        -  8-12 weeks post nCRT completion surgery will be performed, based on each patient's
           performance status and response to nCRT

        -  Histopathological samples of the excised tumor and lymph nodes will be used for
           diagnosis, staging and description of qualitative and quantitative parameters Routine
           clinical and radiological follow-up for 24 months (for the scope of this study) will
           follow the standard clinical workflow assigned to this group of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2020</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">May 16, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to neoadjuvant treatment -MRI</measure>
    <time_frame>0-36 months</time_frame>
    <description>MRI component including Dynamic Contrast Enhanced (DCE); quantitative evaluation and delta between timepoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to neoadjuvant treatment -PET</measure>
    <time_frame>0-36 months</time_frame>
    <description>PET component -quantitative evaluation and delta between timepoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to neoadjuvant treatment - Histology</measure>
    <time_frame>0-36 months</time_frame>
    <description>Evaluate degree of tumor regression after neoadjuvant therapy according to the Mandard Tumour regression grade ; integrated Immunohistochemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to neoadjuvant treatment -Radiomics</measure>
    <time_frame>0-36 months</time_frame>
    <description>Radiomic features extracted from hybrid imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Imaging parameters as potential predictors of tumor response</measure>
    <time_frame>0- 48 months</time_frame>
    <description>Select imaging parameters that can be considered potential predictors of the responder/non-responder status assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early regression model (ERI)</measure>
    <time_frame>0- 60 months</time_frame>
    <description>Evaluate the ERI model as a predictor of histological response (TRG grade) based on MRI tumor volume assessment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Esophageal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Hybrid PET/MRI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For the purposes of the study, in addition to standard imaging (EUS and CT scan), a fully integrated hybrid PET/MRI (PET/MRI) study with FDG will replace the Standard PET (pre-surgical evaluation) used for evaluating distant metastases and will be considered as the add-on procedure at three time points. The additional evaluation for patients is that during nCRT treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hybrid PET/MRI</intervention_name>
    <description>An additional intermediate 18-FDG PET/MRI will be performed during neoadjuvant chemo-radiation therapy. Routine pre-treatment work-up PET/MRI will replace PET alone.</description>
    <arm_group_label>Hybrid PET/MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  biopsy-proven esophageal or junctional carcinomas (either adenocarcinoma (AC) or
             squamous cell carcinoma (SCC) for which an Ivor-Lewis transthoracic esophagectomy with
             supramesocolic and mediastinal lymphadenectomy is indicated;

          -  visible tumor on pre-treatment imaging;

          -  â‰¥ 18 years of age;

          -  signed informed consent.

        Exclusion Criteria:

          -  - incomplete preoperative imaging assessment;

          -  contraindications to neoadjuvant treatment;

          -  contraindications to preoperative imaging (such as pacemaker, allergy to contrast
             agents);

          -  inability to complete imaging examinations (i.e. severe claustrophobia);

          -  contraindication to surgery (comorbidities, distant metastatic disease (imaging
             confirmed));

          -  pregnant or lactating women

          -  severe hypersensitivity to gadobutrol or fludeoxyglucose F18.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco De Cobelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Ospedale San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco De Cobelli, MD</last_name>
    <phone>+3926432529</phone>
    <email>decobelli.francesco@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Steidler</last_name>
    <phone>+3926436111</phone>
    <email>steidler.stephanie@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Deaprtment of Radiology, IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Steidler, PhD</last_name>
      <phone>+390226436111</phone>
      <email>steidler.stephanie@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Francesco De Cobelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Riccardo Rosati, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Francesco De Cobelli</investigator_full_name>
    <investigator_title>MD, Chair Radiology Department</investigator_title>
  </responsible_party>
  <keyword>response</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>PET/MRI</keyword>
  <keyword>radiomics</keyword>
  <keyword>GEJ cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

